Navigation Links
Gains Against Heart Failure Reported
Date:11/11/2008

Exercise, medications prove worth against the condition, doctors say

TUESDAY, Nov. 11 (HealthDay News) -- Researchers are reporting new ways to use exercise and medications to manage and improve the lives of people with heart failure, a condition that affects more than 5 million Americans.

One study found a small, 7 percent reduction in death or hospitalization rates from any cause, as well as a reduction in cardiovascular mortality and heart failure hospitalizations, among heart-failure patients who followed a specific exercise regimen.

"This is the largest and most comprehensive study of exercise training in patients with heart failure," said study lead author Dr. Christopher O'Connor, director of the Duke University Heart Failure Program in Durham, N.C. "It supports a structured exercise training program for patients with reduced left ventricular function and heart failure symptoms, in addition to evidence-based therapy."

O'Connor spoke along with authors of other studies at a Tuesday news conference at the American Heart Association's annual scientific sessions, in New Orleans.

Half the patients in O'Connor's study were randomly selected to receive standard medical therapy plus advice on how to exercise. The other half -- the "intervention arm" -- received supervised exercise training before a transition to home-based exercise, usually a treadmill. The goal was to work up to 40 minutes of moderate-intensity exercise at home five times a week for two-and-a-half years. The second group also received follow-up phone calls monitoring exercise progress.

The next goal is to figure out what sort of exercise is most beneficial and how to get people, not just heart-failure patients, to adhere regularly to an exercise program, Dr. Philip Poole-Wilson of Imperial College London and the British Heart Foundation, said at the news conference.

"The study also showed the exercise was safe, but safety without benefit is a bit dull really," Wilson added.

In other research presented Tuesday, a phase II trial found that interferon, a drug used for both hepatitis and neurological disorders such as multiple sclerosis, eliminated or reduced three viruses from heart-failure patients who had evidence of persistent viral infection.

There was also a slight trend toward better cardiac function and quality of life, though not a statistically significant one, the German study authors said.

"Future trials will test clinical efficacy and how that balances the inconvenience and cost," said Dr. Michael Felker, of the Duke Heart Center. One course of the drug costs about $10,000, and patients need to receive injections every other day.

Another study presented Tuesday found that a so-called biomarker -- a hormone called mid-regional pro-adrenomedullin (MR-pro-ADM) -- was superior to the best established biomarkers for predicting if patients coming to an emergency room with shortness of breath and a diagnosis of heart failure would be dead or alive at 90 days. The marker was even better at predicting outcomes at 30 days, the study authors said.

"Taking a simple blood sample at the time of admission and being able to predict prognosis for 30 days adds to the ability to triage patients and push those patients with the highest medical need to the front line of medical care," said Dr. Stefan D. Anker of Charite Medical School in Berlin, Germany.

But, Dr. Milton Packer, chair of the Department of Clinical Sciences at the University of Texas Southwestern Medical Center at Dallas, questioned whether medicine really needs another biomarker for this purpose. "You can't use this to push patients to the front of the line, because everyone should get optimal therapy for chronic heart failure," he said.

More information

The American Heart Association has more on heart failure.



SOURCES: Nov. 11, 2008, news conference at the American Heart Association scientific sessions, New Orleans, with: Christopher O'Connor, M.D., director, Duke University Heart Failure Program, Durham, N.C.; Philip Poole-Wilson, M.D., Imperial College London and British Heart Foundation; Michael Felker, M.D., Duke Heart Center, Durham, N.C.; Stefan D. Anker, M.D., Charite Medical School, Berlin, Germany; Milton Packer, M.D., University of Texas Southwestern Medical Center at Dallas


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Despite overeating, morbidly obese mice gain protection against diabetes
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
8. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
9. $52.5 Million Settlement Against Sepracor Inc. Approved
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: